MAM
25 per cent drop in number of brands active on cinema: CAM Report
MUMBAI: Interactive Television in collaboration with IPSOS-MEDIA CT has released the CAM report for the month of September 2014. It includes detailed trends for the movie Finding Fanny. The report documents specifics including presence of each category and brands in cinema, brand recall, placement and distribution strategy of each brand and traces the developments in the Indian cinema advertising. The report examined advertising investments in Indian multiplexes or theatres and offers an overview of where the money is flowing in cinema advertising.
Some of the key highlights of the report are: Food and beverages, beauty and personal care and media retained their position of top three categories on cinema in last 13 months. Electrical Equipment category has risen from 43 per cent in August to 74 per cent in September due to increase in spending of Syska LED lights on cinema screens. Syska LED is present in 3/4th of the screens but the number of spots is much higher than the top brand Chocon.
Elaborating on the report Interactive Television CEO Ajay Mehta said “CAM completed 13 rounds of audit with the movie Finding Fanny. One can observe that there has been 25 per cent drop in number of brands active on cinema with the movie Finding Fanny as compared to Singham Returns. Due to festive season the ad duration for 30/60sec is prominent with the majority of brands. Also, 238 total brands were active via cinema advertising during September 2014 audit, out of which 39 brands were screened on cinema for the first time.”
Most brands prefer the During Interval Spot (70 per cent) over the Before Movie spot (30 per cent).But brands like HDFC Life, Kurkure, 7up and Vicco Vajradanti Toothpaste prefer before movie slots. Food and Beverages shows a slight increase due to Chocon and Kurkure.
Also the difference between the top brand recalled and the others is quite high. The report also highlights that Chocon is the top Brand played in north zone theatres followed by OLX.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
